<DOC>
	<DOCNO>NCT00002377</DOCNO>
	<brief_summary>To investigate efficacy safety RS-79070 use induction therapy patient newly diagnose peripheral retinitis . To assess effect induction maintenance level dose RS-79070 CMV viral load , estimate plasma CMV PCR . To assess pharmacokinetics ganciclovir follow administration RS-79070 target population .</brief_summary>
	<brief_title>A Comparison Valganciclovir Ganciclovir Treatment Cytomegalovirus ( CMV ) Eyes</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Documented AIDS diagnosis Newly diagnose peripheral CMV retinitis More 3 week previous therapy CMV retinitis</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2005</verification_date>
</DOC>